Last 12 months
Inside the activity.
0 purchase rows · 2 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 1 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 26, 2017 Filed Oct 30, 2017 20:54 UTC |
HIGGINS JOHN LDirector
|
GrantStock Option (right to buy) · Derivative | 3,125 | $0.00 Strike: $125.05 | $0.00 |
DisclosureSEC source: 0001562180-17-003377 · primarydocument.xml · derivative · entry 2 HIGGINS JOHN L · CIK 0001208906 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,125 Underlying: Common Stock · 3,125 shares Expires 2027-10-27 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/26/18) or the date of Bio-Techne's 2018 annual meeting of shareholders. Read SEC document |
| October 26, 2017 Filed Oct 30, 2017 20:54 UTC |
HIGGINS JOHN LDirector
|
GrantCommon Stock | 739 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-17-003377 · primarydocument.xml · nonDerivative · entry 1 HIGGINS JOHN L · CIK 0001208906 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,012 Read SEC document |
| October 26, 2017 Filed Oct 30, 2017 20:53 UTC |
Nusse RoelandDirector
|
GrantStock Option (right to buy) · Derivative | 3,125 | $0.00 Strike: $125.05 | $0.00 |
DisclosureSEC source: 0001562180-17-003376 · primarydocument.xml · derivative · entry 2 Nusse Roeland · CIK 0001492695 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,125 Underlying: Common Stock · 3,125 shares Expires 2027-10-26 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/26/18) or the date of Bio-Techne's 2018 annual meeting of shareholders. Read SEC document |
| October 26, 2017 Filed Oct 30, 2017 20:53 UTC |
Nusse RoelandDirector
|
GrantCommon Stock | 739 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-17-003376 · primarydocument.xml · nonDerivative · entry 1 Nusse Roeland · CIK 0001492695 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,712 Read SEC document |
| October 26, 2017 Filed Oct 30, 2017 20:50 UTC |
WIENS HAROLD JDirector
|
GrantStock Option (right to buy) · Derivative | 3,125 | $0.00 Strike: $125.05 | $0.00 |
DisclosureSEC source: 0001562180-17-003374 · primarydocument.xml · derivative · entry 2 WIENS HAROLD J · CIK 0001197788 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,125 Underlying: Common Stock · 3,125 shares Expires 2027-10-26 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/26/18) or the date of Bio-Techne's 2018 annual meeting of shareholders. Read SEC document |
| October 26, 2017 Filed Oct 30, 2017 20:50 UTC |
WIENS HAROLD JDirector
|
GrantCommon Stock | 739 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-17-003374 · primarydocument.xml · nonDerivative · entry 1 WIENS HAROLD J · CIK 0001197788 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,212 Read SEC document |
| October 26, 2017 Filed Oct 30, 2017 20:46 UTC |
Dinarello Charles ADirector
|
GrantStock Options (Right to buy) · Derivative | 3,125 | $0.00 Strike: $125.05 | $0.00 |
DisclosureSEC source: 0001562180-17-003373 · primarydocument.xml · derivative · entry 2 Dinarello Charles A · CIK 0001344987 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,125 Underlying: Common Stock · 3,125 shares Expires 2027-10-26 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/26/2017) or the date of Bio-Techne 2018 annual meeting of shareholders. Read SEC document |
| October 26, 2017 Filed Oct 30, 2017 20:46 UTC |
Dinarello Charles ADirector
|
GrantCommon Stock | 739 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-17-003373 · primarydocument.xml · nonDerivative · entry 1 Dinarello Charles A · CIK 0001344987 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,212 Read SEC document |
| October 26, 2017 Filed Oct 31, 2017 15:37 UTC |
KEEGAN JOSEPH DDirector
|
GrantStock Options (Right to buy) · Derivative | 3,125 | $0.00 Strike: $125.05 | $0.00 |
DisclosureSEC source: 0001562180-17-003392 · primarydocument.xml · derivative · entry 2 KEEGAN JOSEPH D · CIK 0001260556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,125 Underlying: Common Stock · 3,125 shares Expires 2027-10-26 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/26/2017) or the date of Bio-Techne 2018 annual meeting of shareholders. Read SEC document |
| October 26, 2017 Filed Oct 31, 2017 15:37 UTC |
KEEGAN JOSEPH DDirector
|
GrantCommon Stock | 739 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-17-003392 · primarydocument.xml · nonDerivative · entry 1 KEEGAN JOSEPH D · CIK 0001260556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 739 Read SEC document |
| October 10, 2017 Filed Oct 12, 2017 20:24 UTC |
LUCAS ROGER CDirector
|
SaleCommon Stock | 100 | $121.96 | $12,195.50 |
DisclosureSEC source: 0001562180-17-003253 · primarydocument.xml · nonDerivative · entry 1 LUCAS ROGER C · CIK 0000902080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,870 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 1, 2016. Read SEC document |
| September 08, 2017 Filed Sep 12, 2017 21:02 UTC |
LUCAS ROGER CDirector
|
SaleCommon Stock | 100 | $120.94 | $12,093.83 |
DisclosureSEC source: 0001562180-17-002935 · primarydocument.xml · nonDerivative · entry 1 LUCAS ROGER C · CIK 0000902080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,970 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 1, 2016. Read SEC document |
| September 06, 2017 Filed Sep 8, 2017 20:44 UTC |
HOLBROOK KAREN ADirector
|
SaleCommon Stock | 1,059 | $121.73 | $128,909.10 |
DisclosureSEC source: 0001562180-17-002919 · primarydocument.xml · nonDerivative · entry 1 HOLBROOK KAREN A · CIK 0001288295 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 914 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $121.72 to $121.728, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 12, 2017 Filed Aug 15, 2017 20:44 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
GrantStock Option (Right to Buy) · Derivative | 66,849 | $0.00 Strike: $94.35 | $0.00 |
DisclosureSEC source: 0000914190-17-000238 · edgar.xml · derivative · entry 5 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,849 Underlying: Common Stock · 66,849 shares Expires 2021-08-12 F6 · derivative.exercise_date: Fully exercisable pursuant to achievement of performance goals. F7 · balance_after: On August 12, 2014, the reporting person was granted an option to purchase 80,460 shares of common stock (previously reported). The option would vest in full or in part on August 12, 2017 if certain performance goals were achieved during each of the 2015, 2016 and 2017 fiscal years. The performance criteria was determined, resulting in the option vesting as to 66,849 shares. Read SEC document |
| August 12, 2017 Filed Aug 15, 2017 20:44 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
Exercise / conversionCommon Stock | 9,248 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000914190-17-000238 · edgar.xml · nonDerivative · entry 1 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,278 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On August 12, 2014, the reporting person was granted 11,129 restricted stock units (previously reported). The restricted stock units would vest in full or in part on August 12, 2017 if certain performance goals were achieved during each of the 2015, 2016 and 2017 fiscal years. The performance criteria was determined, resulting in the restricted stock unit vesting as to 9,248 shares. F2 · price: Restricted stock units convert into common stock on a one-for-one basis. F3 · balance_after: Includes (i) 10,203 shares for which the risk of forfeiture will lapse pursuant to achievement of performance goals; (ii) 3,841 shares for which the risks of forfeiture will lapse on August 7, 2018; and (iii) 16,653 shares for which the risks of forfeiture will lapse with respect to 5,551 shares on each of August 18, 2017, August 18, 2018 and August 18, 2019. Read SEC document |
| August 10, 2017 Filed Aug 14, 2017 20:24 UTC |
LUCAS ROGER CDirector
|
SaleCommon Stock | 100 | $114.30 | $11,430.00 |
DisclosureSEC source: 0001562180-17-002667 · primarydocument.xml · nonDerivative · entry 1 LUCAS ROGER C · CIK 0000902080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,070 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 1, 2016. Read SEC document |
| July 10, 2017 Filed Jul 12, 2017 20:34 UTC |
LUCAS ROGER CDirector
|
SaleCommon Stock | 100 | $116.86 | $11,686.00 |
DisclosureSEC source: 0001562180-17-002467 · primarydocument.xml · nonDerivative · entry 1 LUCAS ROGER C · CIK 0000902080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,170 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 1, 2016. Read SEC document |
| July 09, 2017 Filed Jul 11, 2017 21:30 UTC |
Gould Kevin SSVP Clinical Controls
|
Tax withholdingCommon Stock | 312 | $117.68 | $36,716.16 |
DisclosureSEC source: 0001562180-17-002466 · primarydocument.xml · nonDerivative · entry 1 Gould Kevin S · CIK 0001662638 · SVP Clinical Controls 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,355 F1 · balance_after: Includes 834 shares of restricted stock units that vest on 7/9/18. Read SEC document |
| July 01, 2017 Filed Jul 5, 2017 21:53 UTC |
Furlow Brenda S.SVP - General Counsel
|
Tax withholdingCommon Stock | 278 | $117.50 | $32,665.00 |
DisclosureSEC source: 0001562180-17-002422 · primarydocument.xml · nonDerivative · entry 1 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,668 Read SEC document |
| July 01, 2017 Filed Jul 5, 2017 21:46 UTC |
Eansor Norman DavidSVP - Novus Biologicals
|
Tax withholdingCommon Stock | 534 | $117.50 | $62,745.00 |
DisclosureSEC source: 0001562180-17-002413 · primarydocument.xml · nonDerivative · entry 1 Eansor Norman David · CIK 0001270905 · SVP - Novus Biologicals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,402 Read SEC document |
| June 09, 2017 Filed Jun 13, 2017 20:56 UTC |
LUCAS ROGER CDirector
|
SaleCommon Stock | 100 | $113.62 | $11,362.00 |
DisclosureSEC source: 0001562180-17-002258 · primarydocument.xml · nonDerivative · entry 1 LUCAS ROGER C · CIK 0000902080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,270 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 1, 2016. Read SEC document |
| May 31, 2017 Filed May 31, 2017 20:58 UTC |
Dinarello Charles ADirector
|
SaleCommon Stock | 5,000 | $111.37 | $556,861.50 |
DisclosureSEC source: 0001562180-17-002102 · primarydocument.xml · nonDerivative · entry 2 Dinarello Charles A · CIK 0001344987 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,473 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.3699 to $111.3790, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 26, 2017 Filed May 31, 2017 20:58 UTC |
Dinarello Charles ADirector
|
Exercise / conversionStock Options (Right to buy) · Derivative | 5,000 | $0.00 Strike: $66.59 | $0.00 |
DisclosureSEC source: 0001562180-17-002102 · primarydocument.xml · derivative · entry 3 Dinarello Charles A · CIK 0001344987 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2017-10-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 26, 2017 Filed May 31, 2017 20:58 UTC |
Dinarello Charles ADirector
|
Exercise / conversionCommon Stock | 5,000 | $66.59 | $332,950.00 |
DisclosureSEC source: 0001562180-17-002102 · primarydocument.xml · nonDerivative · entry 1 Dinarello Charles A · CIK 0001344987 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,473 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 25, 2017 Filed May 30, 2017 20:34 UTC |
HOLBROOK KAREN ADirector
|
Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $66.59 | $0.00 |
DisclosureSEC source: 0001562180-17-002080 · primarydocument.xml · derivative · entry 3 HOLBROOK KAREN A · CIK 0001288295 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2017-10-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 25, 2017 Filed May 30, 2017 20:34 UTC |
HOLBROOK KAREN ADirector
|
SaleCommon Stock | 5,000 | $111.15 | $555,773.00 |
DisclosureSEC source: 0001562180-17-002080 · primarydocument.xml · nonDerivative · entry 2 HOLBROOK KAREN A · CIK 0001288295 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,973 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.02 to $111.355, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 25, 2017 Filed May 30, 2017 20:34 UTC |
HOLBROOK KAREN ADirector
|
Exercise / conversionCommon Stock | 5,000 | $66.59 | $332,950.00 |
DisclosureSEC source: 0001562180-17-002080 · primarydocument.xml · nonDerivative · entry 1 HOLBROOK KAREN A · CIK 0001288295 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,973 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 22, 2017 Filed Jun 1, 2017 20:51 UTC |
LUCAS ROGER CDirector
|
SaleCommon Stock | 1,059 | $110.01 | $116,504.83 |
DisclosureSEC source: 0001562180-17-002110 · primarydocument.xml · nonDerivative · entry 1 LUCAS ROGER C · CIK 0000902080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,370 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.00 to $110.05, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 10, 2017 Filed May 12, 2017 20:16 UTC |
LUCAS ROGER CDirector
|
SaleCommon Stock | 100 | $110.59 | $11,059.00 |
DisclosureSEC source: 0001562180-17-001934 · primarydocument.xml · nonDerivative · entry 1 LUCAS ROGER C · CIK 0000902080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,429 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 1, 2016. Read SEC document |
| April 10, 2017 Filed Apr 12, 2017 20:52 UTC |
LUCAS ROGER CDirector
|
SaleCommon Stock | 78 | $101.13 | $7,888.14 |
DisclosureSEC source: 0001562180-17-001502 · primarydocument.xml · nonDerivative · entry 2 LUCAS ROGER C · CIK 0000902080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,551 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 1, 2016. Read SEC document |
| April 10, 2017 Filed Apr 12, 2017 20:52 UTC |
LUCAS ROGER CDirector
|
SaleCommon Stock | 22 | $101.23 | $2,227.06 |
DisclosureSEC source: 0001562180-17-001502 · primarydocument.xml · nonDerivative · entry 1 LUCAS ROGER C · CIK 0000902080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,529 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 1, 2016. Read SEC document |
| March 31, 2017 Filed Apr 4, 2017 22:20 UTC |
Hippel JamesChief Financial Officer
|
Tax withholdingCommon Stock | 800 | $101.65 | $81,320.00 |
DisclosureSEC source: 0001562180-17-001448 · primarydocument.xml · nonDerivative · entry 1 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,079 F1 · shares: The reporting person has elected to satisfy his withholding obligation in connection with the vesting of a prior restricted stock unit grant by directing the Company to withhold shares otherwise issuable pursuant to the previously reported grant. Read SEC document |
| March 10, 2017 Filed Mar 14, 2017 20:43 UTC |
LUCAS ROGER CDirector
|
SaleCommon Stock | 21 | $107.81 | $2,264.01 |
DisclosureSEC source: 0001562180-17-001257 · primarydocument.xml · nonDerivative · entry 2 LUCAS ROGER C · CIK 0000902080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,629 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 1, 2016. Read SEC document |
| March 10, 2017 Filed Mar 14, 2017 20:43 UTC |
LUCAS ROGER CDirector
|
SaleCommon Stock | 79 | $107.76 | $8,513.04 |
DisclosureSEC source: 0001562180-17-001257 · primarydocument.xml · nonDerivative · entry 1 LUCAS ROGER C · CIK 0000902080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,650 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 1, 2016. Read SEC document |
| February 10, 2017 Filed Feb 14, 2017 22:03 UTC |
LUCAS ROGER CDirector
|
SaleCommon Stock | 100 | $102.60 | $10,260.00 |
DisclosureSEC source: 0001562180-17-000678 · primarydocument.xml · nonDerivative · entry 1 LUCAS ROGER C · CIK 0000902080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,729 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 1, 2016. Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 23:54 UTC |
Gavin Robert M.Senior V.P. Protein Platforms
|
Exercise / conversionRestricted Stock Units · Derivative | 1,667 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-17-000026 · edgar.xml · derivative · entry 5 Gavin Robert M. · CIK 0001608023 · Senior V.P. Protein Platforms 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one shares of Bio-Techne common stock. F4 · derivative.exercise_date: On 2/1/17, the Board of Directors authorized discretionary vesting for 1,667 performance RSUs. The remainder of the performance RSUs were foreited. F4 · derivative.expiration_date: On 2/1/17, the Board of Directors authorized discretionary vesting for 1,667 performance RSUs. The remainder of the performance RSUs were foreited. Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 23:54 UTC |
Gavin Robert M.Senior V.P. Protein Platforms
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 33,333 | $0.00 Strike: $93.32 | $0.00 |
DisclosureSEC source: 0000914190-17-000026 · edgar.xml · derivative · entry 3 Gavin Robert M. · CIK 0001608023 · Senior V.P. Protein Platforms 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,667 Underlying: Common Stock · 33,333 shares Expires 2021-07-31 F2 · derivative.exercise_date: On 2/1/17, the Board of Directors authorized discretionary vesting for 16,667 performance options. The remainder of the performance options were forfeited. Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 23:54 UTC |
Gavin Robert M.Senior V.P. Protein Platforms
|
Exercise / conversionCommon Stock | 1,667 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-17-000026 · edgar.xml · nonDerivative · entry 1 Gavin Robert M. · CIK 0001608023 · Senior V.P. Protein Platforms 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,667 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 10, 2017 Filed Jan 12, 2017 22:02 UTC |
LUCAS ROGER CDirector
|
SaleCommon Stock | 100 | $103.57 | $10,357.00 |
DisclosureSEC source: 0001562180-17-000230 · primarydocument.xml · nonDerivative · entry 1 LUCAS ROGER C · CIK 0000902080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,829 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 1, 2016. Read SEC document |
| December 09, 2016 Filed Dec 13, 2016 21:31 UTC |
LUCAS ROGER CDirector
|
SaleCommon Stock | 100 | $108.92 | $10,892.48 |
DisclosureSEC source: 0000914190-16-000956 · edgar.xml · nonDerivative · entry 1 LUCAS ROGER C · CIK 0000902080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,929 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 1, 2016. Read SEC document |
| November 29, 2016 Filed Dec 1, 2016 21:30 UTC |
HOLBROOK KAREN ADirector
|
SaleCommon Stock | 1,000 | $106.73 | $106,733.00 |
DisclosureSEC source: 0000914190-16-000915 · edgar.xml · nonDerivative · entry 1 HOLBROOK KAREN A · CIK 0001288295 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,973 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $106.54 to $106.90 inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 16, 2016 Filed Nov 18, 2016 21:33 UTC |
LUCAS ROGER CDirector
|
SaleCommon Stock | 100 | $105.75 | $10,575.00 |
DisclosureSEC source: 0000914190-16-000872 · edgar.xml · nonDerivative · entry 1 LUCAS ROGER C · CIK 0000902080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,029 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 12, 2016. Read SEC document |
| October 27, 2016 Filed Oct 31, 2016 21:10 UTC |
LUCAS ROGER CDirector
|
GrantStock Option (right to buy) · Derivative | 3,985 | $0.00 Strike: $101.19 | $0.00 |
DisclosureSEC source: 0000914190-16-000864 · edgar.xml · derivative · entry 3 LUCAS ROGER C · CIK 0000902080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,985 Underlying: Common Stock · 3,985 shares Expires 2026-10-26 F2 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/27/17) or the date of Bio-Techne's 2017 annual meeting of shareholders. Read SEC document |
| October 27, 2016 Filed Oct 31, 2016 21:10 UTC |
LUCAS ROGER CDirector
|
GrantCommon Stock | 914 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-16-000864 · edgar.xml · nonDerivative · entry 2 LUCAS ROGER C · CIK 0000902080 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,129 Read SEC document |
| October 27, 2016 Filed Oct 31, 2016 20:16 UTC |
Dinarello Charles ADirector
|
GrantStock Option (right to buy) · Derivative | 3,985 | $0.00 Strike: $101.19 | $0.00 |
DisclosureSEC source: 0000914190-16-000858 · edgar.xml · derivative · entry 2 Dinarello Charles A · CIK 0001344987 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,985 Underlying: Common Stock · 3,985 shares Expires 2026-10-26 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/27/17) or the date of Bio-Techne's 2017 annual meeting of shareholders. Read SEC document |
| October 27, 2016 Filed Oct 31, 2016 20:16 UTC |
Dinarello Charles ADirector
|
GrantCommon Stock | 914 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-16-000858 · edgar.xml · nonDerivative · entry 1 Dinarello Charles A · CIK 0001344987 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,473 Read SEC document |
| October 27, 2016 Filed Oct 31, 2016 20:18 UTC |
WIENS HAROLD JDirector
|
GrantStock Option (right to buy) · Derivative | 3,985 | $0.00 Strike: $101.19 | $0.00 |
DisclosureSEC source: 0000914190-16-000862 · edgar.xml · derivative · entry 2 WIENS HAROLD J · CIK 0001197788 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,985 Underlying: Common Stock · 3,985 shares Expires 2026-10-26 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/27/17) or the date of Bio-Techne's 2017 annual meeting of shareholders. Read SEC document |
| October 27, 2016 Filed Oct 31, 2016 20:18 UTC |
WIENS HAROLD JDirector
|
GrantCommon Stock | 914 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-16-000862 · edgar.xml · nonDerivative · entry 1 WIENS HAROLD J · CIK 0001197788 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,473 Read SEC document |
| October 27, 2016 Filed Oct 31, 2016 20:55 UTC |
BAUMGARTNER ROBERT VDirector
|
GrantStock Option (right to buy) · Derivative | 3,985 | $0.00 Strike: $101.19 | $0.00 |
DisclosureSEC source: 0000914190-16-000863 · edgar.xml · derivative · entry 2 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,985 Underlying: Common Stock · 3,985 shares Expires 2026-10-26 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/27/17) or the date of Bio-Techne's 2017 annual meeting of shareholders. Read SEC document |
| October 27, 2016 Filed Oct 31, 2016 20:55 UTC |
BAUMGARTNER ROBERT VDirector
|
GrantCommon Stock | 914 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-16-000863 · edgar.xml · nonDerivative · entry 1 BAUMGARTNER ROBERT V · CIK 0001258704 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,973 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.